- Home
- PASG vs CCEL Comparison
PASG vs CCEL Comparison
Compare PASG & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PASG
- CCEL
- Stock Information
- Founded
- PASG 2017
- CCEL 1989
- Country
- PASG United States
- CCEL United States
- Employees
- PASG N/A
- CCEL N/A
- Industry
- PASG Biotechnology: Pharmaceutical Preparations
- CCEL Managed Health Care
- Sector
- PASG Health Care
- CCEL Health Care
- Exchange
- PASG Nasdaq
- CCEL Nasdaq
- Market Cap
- PASG 42.2M
- CCEL 50.0M
- IPO Year
- PASG 2020
- CCEL 1997
- Fundamental
- Price
- PASG $0.61
- CCEL $7.81
- Analyst Decision
- PASG Strong Buy
- CCEL
- Analyst Count
- PASG 3
- CCEL 0
- Target Price
- PASG $8.00
- CCEL N/A
- AVG Volume (30 Days)
- PASG 1.2M
- CCEL 12.9K
- Earning Date
- PASG 11-13-2024
- CCEL 12-31-2024
- Dividend Yield
- PASG N/A
- CCEL 3.13%
- EPS Growth
- PASG N/A
- CCEL N/A
- EPS
- PASG N/A
- CCEL N/A
- Revenue
- PASG N/A
- CCEL $31,838,476.00
- Revenue This Year
- PASG N/A
- CCEL $3.97
- Revenue Next Year
- PASG N/A
- CCEL $0.91
- P/E Ratio
- PASG N/A
- CCEL N/A
- Revenue Growth
- PASG N/A
- CCEL 1.95
- 52 Week Low
- PASG $0.45
- CCEL $4.47
- 52 Week High
- PASG $1.79
- CCEL $9.50
- Technical
- Relative Strength Index (RSI)
- PASG 43.78
- CCEL 42.90
- Support Level
- PASG $0.73
- CCEL $7.60
- Resistance Level
- PASG $0.90
- CCEL $9.10
- Average True Range (ATR)
- PASG 0.13
- CCEL 0.28
- MACD
- PASG -0.02
- CCEL -0.16
- Stochastic Oscillator
- PASG 0.00
- CCEL 14.58
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from cellular processing and cryogenic storage and it derives revenue from processing and testing fees and storage segment.